Drupal.behaviors.print = function(context) {window.print();window.close();}>

Abbott Using Myriad's BRACAnalysis to Stratify Patients for Phase III PARP Inhibitor Breast Cancer Trial

October 27, 2010

Abbott Using Myriad's BRACAnalysis to Stratify Patients for Phase III PARP Inhibitor Breast Cancer Trial

Myriad and Abbott have extended existing Rx/Dx partnership to personalize treatment with veliparib into late-stage studies.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories